Hutchmed China — TickStock

Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for oncology and other therapeutic areas. The company operates primarily in China with an expanding international presence, holding a mid-cap market position on the London Stock Exchange. Hutchmed is in the growth stage with a portfolio of marketed drugs and multiple candidates in clinical development, generating revenue from oncology product sales while investing substantially in R&D.

Sector: Pharma
Market: AIM

Identifiers

Ticker: HCM
Market: AIM
ISIN: KYG4672N1198

Learn more on:

Timeline

Hutchmed's fanregratinib hits 42.5% response rate in bile duct cancer trial

More in Pharma

Cavendish reiterates 'buy' on HUTCHMED with 436p target after 19% share-price slide

ImmuPharma names Bachem as manufacturing partner for Kapiglucagon drug program

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

Health & Bio Today: Thalia Therapeutics acquires AML RNA therapy firm in £2.75m-backed deal, Primary Health Properties, Verici Dx, Beximco Pharmaceuticals, Cambridge Cognition

Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate

Thalia Therapeutics acquires AML RNA therapy company in deal backed by £2.75m raise

Primary Health Properties in advanced talks to form private hospital portfolio joint venture

Deutsche Bank holds GSK at 1,900p as prescription tracker flags mixed product trends

Beximco Pharma delivers first doses of generic cystic fibrosis treatment at 96% discount to US price

Avacta starts dosing patients in AVA6103 trial with cash runway extended to early 2027

Solvonis Therapeutics hits key PK milestone for esketamine AUD programme

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer